Inhibrx Biosciences, Inc.
INBX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$88.61
KIRA · Stoqly’s AI analyst, in plain words
- Inhibrx Biosciences, Inc. had $1.3M of revenue in fiscal 2025, up 550.0% on the year before.
- Its operating margin was −10,386.5%, up 155,337.5 pts: of every 100 in sales, about −10,387 is left after running the business.
- Inhibrx Biosciences, Inc. lost $140M in fiscal 2025.
- Free cash flow was −$130M in fiscal 2025, −9,986.5% of revenue.
- Inhibrx Biosciences, Inc. has $23.7M more cash than debt.
Market cap
$1.4B
P/E
—
Revenue
$1.3M
Net income
−$140M
Free cash flow
−$130M
Operating margin
−10,386.5%
Inhibrx Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+550.0%
Yes. Sales grew 550.0% last year.
Does it make a profit?
−10,773.5%
No. It lost money last year.
Does profit turn into cash?
−9,986.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inhibrx Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Inhibrx Biosciences, Inc.
- CIK
- 0002007919
Inhibrx Biosciences, Inc. · INBX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $1.8M | $0.2M | $1.3M |
| Revenue growth | — | −88.9% | 550.0% |
| Operating margin | −12,178.9% | −165,724.0% | −10,386.5% |
| Net income | −$241M | $1.7B | −$140M |
| Net margin | −13,408.9% | 843,786.0% | −10,773.5% |
| Diluted EPS | −$20.48 | $112.62 | −$9.04 |
| Cash | |||
| Cash from operations | −$193M | −$194M | −$130M |
| Capital expenditure | $4.6M | $2.6M | $0.0M |
| Free cash flow | −$198M | −$197M | −$130M |
| FCF margin | −10,994.6% | −98,503.0% | −9,986.5% |
| Share count change | — | 27.2% | 3.4% |
| Debt and strength | |||
| Cash and short-term investments | $278M | $153M | $124M |
| Debt incl. finance leases | $207M | $0.0M | $101M |
| Shareholders' equity | $43.5M | $134M | $8.0M |
| Current ratio | 5.2x | 3.9x | 3.9x |
| Interest coverage | −6.9x | −24.6x | −11.1x |
| Returns and quality | |||
| Return on equity | −554.8% | 1,905.9% | −197.8% |
| Return on tangible equity | −554.8% | 1,263.3% | −1,752.2% |
| Piotroski F-score | — | 3 | 2 |
| Altman Z'' | −6.0 | −6.9 | −7.2 |
Insiders bought, 12 months
$6.3M
3 insiders
Insiders sold, 12 months
$0.3M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inhibrx Biosciences, Inc. · INBX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $88.61 a share, the company is worth $1.4B.
Source: SEC EDGAR XBRL filings (CIK 0002007919). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.